Best Medication for Triglycerides
For patients with moderate hypertriglyceridemia (150-499 mg/dL) already on statin therapy who have cardiovascular disease or elevated cardiovascular risk, icosapent ethyl (EPA) is the medication of choice for additional triglyceride lowering and cardiovascular risk reduction. 1
Treatment Algorithm Based on Triglyceride Level
Moderate Hypertriglyceridemia (150-499 mg/dL)
First-line approach:
- Optimize lifestyle interventions (weight loss, physical activity, alcohol moderation, reduced saturated fat intake)
- Ensure statin therapy is maximized if LDL-lowering is also needed 2
Add-on pharmacotherapy:
Icosapent ethyl (EPA) is conditionally recommended for patients with ASCVD or diabetes plus additional risk factors on background statin therapy 1
- Provides small reduction in myocardial infarction
- Important caveat: Small increased risk of atrial fibrillation and major bleeding—requires shared decision-making 1
Avoid EPA plus DHA combinations (standard fish oil)—these are conditionally recommended against as they show no clinically meaningful cardiovascular benefit 1
Avoid niacin—strongly recommended against due to trivial MI reduction but serious harms including infection, bleeding, and hyperglycemic events requiring hospitalization 1
Severe Hypertriglyceridemia (≥500 mg/dL)
Primary goal: Prevent acute pancreatitis
Treatment approach:
- Fibrates (gemfibrozil or fenofibrate) are first-line 2
- Aggressively optimize glycemic control if diabetic 2
- Severe dietary fat restriction (<10% of calories) 3
- High-dose statins may be added if LDL is also elevated 2
Important note: Insufficient evidence exists for EPA, EPA+DHA, or niacin at these severe levels—no trials reported effects on pancreatitis 1
Very Severe Hypertriglyceridemia (≥1,000 mg/dL)
- Immediate fibrate therapy to reduce pancreatitis risk 4
- Absolute alcohol restriction
- Severe restriction of long-chain fats 4
- Consider omega-3 fatty acids (prescription formulations providing 3-5g EPA+DHA) as adjunct 5
Key Clinical Considerations
Combination therapy risks:
- Gemfibrozil + statin carries highest myositis risk—avoid this combination 2, 3
- Fenofibrate + statin is safer but still requires monitoring for myalgia 4
- Take fibrates in morning, statins in evening to minimize peak concentrations 4
Evidence quality context: The 2025 AACE guidelines 1 represent the most recent high-quality evidence and notably downgrade recommendations for traditional triglyceride therapies. The REDUCE-IT trial demonstrated cardiovascular benefit with icosapent ethyl, but this remains a conditional recommendation with low certainty of evidence due to potential harms.
Common pitfall: Do not use niacin in combination with statins despite older guidelines suggesting this—the FDA no longer approves niacin-statin combination products, and recent evidence shows net harm 1.